The Indian Council of Medical Research (ICMR) has formalized Memorandum of Agreements (MoAs) with several sponsors to initiate first-in-human clinical trials for four novel molecules. This marks a significant advancement in India's pharmaceutical research and development landscape, with the goal of establishing the nation as a key player in early-phase clinical trials.
The collaborations encompass a range of therapeutic areas. Aurigene Oncology Limited will partner with ICMR to study a small molecule for the treatment of multiple myeloma. Indian Immunologicals Limited will collaborate on the development of a Zika vaccine. A seasonal influenza virus vaccine trial will be coordinated with Mynvax Private Limited. Furthermore, ImmunoACT will work with ICMR to advance CAR-T cell therapy for a new indication of chronic lymphocytic leukemia.
"This collaboration reflects our commitment to advancing clinical research in India through strategic public-private partnerships," said Dr. Rajiv Bahl, secretary, department of health research & director general, ICMR. "Establishing phase 1 clinical trial infrastructure is a key component in fostering the development of indigenous molecules and cutting-edge treatments. Our vision is to expand this network further, ensuring that India continues to lead in the development of innovative and affordable healthcare solutions."
The ICMR Network for phase 1 clinical trials comprises four strategically located institutions across India: KEMH & GSMC, Mumbai; ACTREC, Navi Mumbai; SRM MCH&RC, Kattankulathur; and PGIMER, Chandigarh. A Central Coordinating Unit at ICMR headquarters in New Delhi supports the network. This infrastructure is designed to enhance India’s capacity to conduct early-phase clinical trials, ensuring smooth and effective operations through robust infrastructure and dedicated manpower at each trial site.
Union health and family welfare minister, J P Nadda, stated that this strategic collaboration between ICMR and industry and academic partners is a key milestone in providing affordable and accessible cutting-edge treatments for all citizens. The initiative aligns with the government’s vision of a “Viksit Bharat” (Developed India), as highlighted by Dr. Bahl, referencing ICMR’s pivotal role in the development of Covaxin in collaboration with Bharat Biotech as a testament to the organization’s commitment to affordable and accessible healthcare.
